Meta AnalysisID 2620
经皮冠状动脉介入治疗稳定性冠心病期间使用糖蛋白IIa-IIIb抑制剂的安全性与有效性：Meta分析
CRD42022348612
Glycoprotein IIa-IIIb (GPIIa-IIIb) inhibitors are potent intravenous antiplatelet agents frequently used in acute coronary syndromes alongside dual antiplatelet therapy (DAPT) and intravenous heparin. The benefit of GPII
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2620
- Evidence Id
- 11178
- Core Evidence Id
- 11178
- Source Meta Analysis Id
- 2572
- Herb2 Meta Analysis Id
- HBMA002572
- Crd Id
- CRD42022348612
- Title
- Safety and Efficacy of glycoprotein IIa-IIIb inhibitor during percutaneous intervention for stable coronary artery disease: a Meta-analysis.
- Review Question
- Glycoprotein IIa-IIIb (GPIIa-IIIb) inhibitors are potent intravenous antiplatelet agents frequently used in acute coronary syndromes alongside dual antiplatelet therapy (DAPT) and intravenous heparin. The benefit of GPIIa-IIIB inhibitors in stable coronary syndromes managed with percutaneous coronary intervention is less clear. This meta-analysis will seek to identify if there are improved outcomes when GPIIa/IIIb inhibitors are used with PCI for coronary syndromes, compared to standard of care. We will also investigate if the use of these agents is associated with any increase in adverse events.
- Study Type Included
- Randomised controlled trials only. Only studies published in English, or with an English translation, will be included.
- Condition Being Studied
- Stable coronary artery disease/chronic coronary syndromes.
- Participant
- Inclusion criteria: 1. Patients with stable coronary artery disease/chronic coronary syndromes undergoing percutaneous coronary intervention 2. Use of GP IIa-IIIb inhibitors at time of, or immediately after PCI 3. Follow up data available at least 28 days or later from intervention. Exclusion criteria: Patients with an acute coronary syndrome (STEMI, NSTEMI or unstable angina).
- Animal
- Human Disease Modelled
- Intervention
- Intervention: use of glycoprotein IIa-IIIb inhibitors (tirofiban, abciximab, eptifibatide) at or immediately after percutaneous coronary intervention, in conjunction with usual therapy (dual antiplatelet therapy and intravenous heparin)
- Comparator Control
- Antiplatelet therapy and intravenous heparin
- Main Outcome
- Main outcome: 1. Major adverse cardiovascular events (non-fatal MI, non-fatal stroke and cardiovascular death) 2. Need for repeat revascularisation
- Outcome Measure
- Additional Outcome
- Additional outcomes: 1. Angina score or quality of life questionnaires 2. Acute stent thrombosis or procedure related MACE 3. Major bleeding
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Coronary Artery Disease; Glycoproteins; Humans
- Contact
- Daniel Brieger [email protected]
- Organisational Affiliation
- Department of Cardiology, Royal North Shore Hospital
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Australia
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-07-26
- Registration Date
- 2022-08-06
- Anticipated Start Date
- 2022-07-25
- Anticipated Completion Date
- 2023-01-27
- Title Cn
- 经皮冠状动脉介入治疗稳定性冠心病期间使用糖蛋白IIa-IIIb抑制剂的安全性与有效性：Meta分析
- Title En
- Safety and Efficacy of glycoprotein IIa-IIIb inhibitor during percutaneous intervention for stable coronary artery disease: a Meta-analysis.
- Bilingual Status
- complete